About ▼ Careers Internship MedBlog Contact us

2010 Weight Management Resolutions Can Be Kept

Smart for Life(R) Cookie Diet's Variety of Products Are Ideal Solution to Keeping That Nagging Resolution

CONTACT:

Lisa Goodman
1-561-394-5300 ext. 202
[email protected]

Latest Press Release on Obesity News

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dos...

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

CAMBRIDGE, Mass. , March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery eng...

Obesity Action Coalition (OAC) Mobilizes Advocates on Capitol Hill to Mark the Start of Obesity Care Week 2024

WASHINGTON , March 1, 2024 /PRNewswire/ -- To kick off Obesity Care Week 2024, more than 60 advocates with the Obesity Action Coalition (OAC) will gather on Capitol Hill to meet with ...

NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass. , Feb. 29, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a ...

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food ...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close